Immediate Impact

49 standout
Sub-graph 1 of 21

Citing Papers

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
2025 Standout
Lung microbiome: new insights into the pathogenesis of respiratory diseases
2024 Standout
12 intermediate papers

Works of Isabelle Danner‐Boucher being referenced

Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis
2022
Disseminated Scedosporium / Pseudallescheria Infection after Double-Lung Transplantation in Patients with Cystic Fibrosis
2010
and 3 more

Author Peers

Author Last Decade Papers Cites
Isabelle Danner‐Boucher 172 171 65 214 20 406
Grzegorz Kofla 48 163 95 205 21 457
Mary S. Mathews 24 201 56 189 23 449
Katie Dunne 103 90 55 198 15 442
J.L. Yntema 141 109 56 108 20 378
Katharina Seeber 45 333 27 324 18 445
Kenneth J. Hammerman 76 229 22 226 14 372
Charles A. Brasher 47 325 53 250 19 431
Shuying Li 77 180 70 171 28 449
Jackie Rendall 243 74 19 129 16 360
William A. Winn 39 298 37 252 15 403

All Works

Loading papers...

Rankless by CCL
2026